NCT01833143 2020-08-04
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
Clinical Trials
18 trialsNCT00064012 2019-12-13
Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00798720 2019-12-13
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00200382 2018-08-02
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Montefiore Medical Center
Phase 2 Terminated
NCT00458913 2018-07-12
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00362882 2017-12-05
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01633645 2015-09-28
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
University Hospital of Crete
Phase 2 Completed
NCT00513877 2014-12-31
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
Cancer Trials Ireland
Phase 2 Completed
NCT00118144 2014-08-21
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00068289 2013-06-24
Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00118183 2013-06-04
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00075751 2013-02-28
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00346645 2013-02-06
A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT00040768 2013-01-16
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00117351 2011-02-17
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00283634 2011-02-17
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00343720 2008-03-13
Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00051974 2008-02-11
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Completed